Europe Liquid Biopsy Market Size & Outlook, 2024-2030
Related Markets
Europe liquid biopsy market highlights
- The Europe liquid biopsy market generated a revenue of USD 3,647.5 million in 2024.
- The market is expected to grow at a CAGR of 11.5% from 2025 to 2030.
- In terms of segment, blood sample based was the largest revenue generating type in 2024.
- Blood Sample Based is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 3,647.5 million |
| Market revenue in 2030 | USD 7,031.4 million |
| Growth rate | 11.5% (CAGR from 2025 to 2030) |
| Largest segment | Blood sample based |
| Fastest growing segment | Blood Sample Based |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample Based |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, Europe region accounted for 30.8% of the global liquid biopsy market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,585.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample based was the largest segment with a revenue share of 81.38% in 2024. Horizon Databook has segmented the Europe liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounts for the largest revenue share of the liquid biopsy market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which can boost clinical research prospects in the region.
In Europe, high number of liquid biopsy tests have received the CE mark of approval for commercial usage. Most European countries use liquid biopsy tests as a part of cancer screening for various types of cancer, from breast cancer to lung cancer.
As a flagship action, the initiative focuses on establishing a digital infrastructure that connects resources and databases of cancer imaging data across the EU. These factors are expected to drive the market in the region.
Reasons to subscribe to Europe liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe liquid biopsy market , including forecasts for subscribers. This continent databook contains high-level insights into Europe liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe liquid biopsy market size, by country, 2018-2030 (US$M)
Europe Liquid Biopsy Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
